Biotech & Medicine
186 articles RSS
Largest TB Vaccine Trial in Decades Finds VPM1002 Halves Extrapulmonary Risk but Falls Short of Broad Protection
Phase 3 PreVenTB trial of 12,717 people across India shows VPM1002 cuts extrapulmonary tuberculosis by 50%, but neither candidate prevents pulmonary TB or latent infection.
Prime Medicine Seeks FDA Accelerated Approval for First-Ever Prime Editing Therapy After Two Patients Achieve Durable Immune Restoration
Prime Medicine is pursuing accelerated approval for PM359, an autologous prime editing therapy that restored immune function in both patients treated for chronic granulomatous disease, marking the first clinical use of prime editing technology.
UCSF and Berkeley Scientists Engineer CAR-T Cells Directly Inside the Body, Clearing Tumors in Mice With a Single Injection
A two-particle gene-editing system published in Nature creates functional CAR-T cells in vivo, eliminating the costly weeks-long manufacturing process and clearing leukemia, myeloma, and solid tumors in preclinical models.
McGill Researchers Map 38 Neuropeptide Receptors Across the Human Brain, Revealing How Ancient Signaling Molecules Shaped Higher Cognition
A Nature Neuroscience study from the Montreal Neurological Institute constructs the first whole-brain atlas of 14 neuropeptide families, uncovering a cortical-subcortical gradient and evidence that neuropeptide refinement coincided with the evolutionary emergence of the neocortex.
BioNTech's Personalized mRNA Vaccine Keeps 11 of 14 Triple-Negative Breast Cancer Patients Relapse-Free for Up to Six Years
A first-in-human trial published in Nature shows BioNTech's individualized neoantigen mRNA vaccine produces durable T cell immunity and sustained disease control in aggressive breast cancer.
FDA Grants Fast-Track Designation to First Bioengineered Liver for Acute Liver Failure After Phase 1 Trial Shows Promise
United Therapeutics' miroliverELAP, an external bioengineered liver built on a decellularized pig scaffold seeded with human cells, receives FDA RMAT designation after all five Phase 1 patients survived treatment.
Hair-Thin Nerve Implants Decode Phantom Leg Movements in Above-Knee Amputees, Opening Path to Neurally Controlled Prosthetics
Ultrathin electrodes in the sciatic nerve and a spiking neural network decoder classify phantom leg movements in above-knee amputees, enabling bidirectional motor control and sensory feedback from one device.
Life Biosciences Raises $80 Million to Fund First Human Trial of Epigenetic Cell Rejuvenation
The Boston biotech closes a Series D round to advance ER-100, the first FDA-cleared therapy that uses partial epigenetic reprogramming to reverse cellular aging in humans.
Continuous Glucose Monitors Split Into Two Markets as Year-Long Implants and OTC Wellness Sensors Reshape Diabetes and Consumer Health
Real-world data from the first year-long implantable CGM arrives as over-the-counter glucose biosensors pivot toward AI-driven wellness coaching, splitting the market between clinical precision and consumer accessibility.
Bipartisan Senate Push Builds Toward Psychedelic Therapy for Veterans as Clinical Evidence Mounts
Two bipartisan Senate bills would create a VA Office of Novel Therapeutics and fund psychedelic research centers, while states enact their own laws and Phase 3 trials advance.
Brain Organoid Science Hits an Inflection Point as Therapies Reach Patients, NIH Builds a National Center, and Nature Calls for Regulation
A decade after the first lab-grown brain models, organoid research is crossing from laboratory curiosity to clinical reality, prompting calls for governance frameworks to match the pace of science.
FDA Accepts Ultragenyx's Gene Therapy Application for Sanfilippo Syndrome, Setting September Decision Date for First-Ever Treatment
The FDA has accepted Ultragenyx's resubmitted BLA for UX111, a one-time gene therapy for the fatal childhood disease Sanfilippo syndrome Type A, with a decision expected by September 19, 2026.